The Medical Imaging & Technology Alliance (MITA)—the trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices—has shared its support of H.R. 2007, the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021, which would require research into Medicaid coverage of uterine fibroids treatments and conduct public education on the availability of treatment options, including non-hysterectomy treatments and procedures.
In a letter to the U.S. House Committee of Energy and Commerce Health Subcommittee, MITA noted that, “Most American women will develop fibroids at some point in their life, with many experiencing pain; discomfort; and in some cases, reproductive challenges. Fibroids are typically removed using invasive surgery that can require up to six weeks of recovery and can result in infertility. There is a need for greater understanding, adoption, and access to noninvasive treatment options, like focused ultrasound, that can remove fibroids while preserving fertility and getting women back to work and their daily activities as soon as the day after treatment.”
The letter concludes by noting that passage of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 would provide much needed resources for evaluation of coverage for noninvasive treatments and improve patient access.
The full letter can be viewed here.